< Back to companies
Ark Bio

Ark Bio

Singapore, Singapore

Ark is an end-to-end solution provider focused on cancer early detection. By harnessing advanced data science and proprietary miRNA detection technology, Ark develops non-invasive and cost-effective blood tests to detect early stage cancers before clinical symptoms appear. The company collaborates extensively with top medical research institutions globally and is spearheading Asia’s largest miRNA clinical studies targeting more than 50,000 participants. Ark is headquartered in Singapore, with R&D, manufacturing and clinical diagnostic operations in China and USA. Ark was founded in early 2018 through the merger of MiRXES and Venturecraft

Only accessible to MedStartr community members. Join now

Company Info

Founded
2018
Website
ark.bio

Categories

CancerPrevention

Disease Areas

Technologies

Data ScienceAdvanced Data AnalyticsMolecular DiagnosticsNon-Invasive Diagnostics
Only accessible to MedStartr community members. Join now

What do you think of Ark Bio?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now